![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Erythropoietin (EPO) is of special interest in the perinatal period in the mother and fetus. On the one hand, thanks to the recent development of highly sensitive radioimmunoassays and the ability to monitor endogenous EPO production, we can now study the physiological aspects of maternal and fetal erythropoiesis and materno-fetal interrelations, and diagnose raised EPO levels as markers of oxygen deficiency. On the other hand, the availability of recombinant human EPO (rHuEPO) permits therapeutic intervention against anaemia during and after pregnancy. This paper reviews available studies showing a rise in maternal and fetal EPO levels in parallel with gestational age and, in certain pathological states of pregnancy, grossly raised EPO levels in amniotic fluid and fetal blood entirely unrelated to maternal values. The theoretical and experimental arguments against transplacental passage of EPO in the human are discussed. Initial results with rHuEPO have shown rapid correction of maternal post-partum anaemia. No studies on its use during pregnancy are available to date.